Impact of hospital formularies on fluoroquinolone prescribing in emergency departments

American Journal of Managed Care

Volumn 13, Issue 5, 2007, Pages 241-248

  Aspinall, Sherrie L ^a,d   Metlay, Joshua P ^b   Maselli, Judith H ^c   Gonzales, Ralph ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG FORMULARY; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARYNGITIS; PNEUMONIA; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINUSITIS;

CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; EMERGENCY SERVICE, HOSPITAL; FLUOROQUINOLONES; FORMULARIES, HOSPITAL; HEALTH SERVICES RESEARCH; HUMANS; LOGISTIC MODELS; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY TRACT INFECTIONS; UNITED STATES;

EID: 34249000346     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Roumie CL, Halasa NB, Grijalva CG, et al. Trends in antibiotic prescribing for adults in the United States - 1995 to 2002. J Gen Intern Med. 2005;20:697-702.
2. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259-268.
3. Ho PL, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701-707.
4. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis. 2005;41:118-121.
5. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003;37:1643-1648.
6. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis. 2004;38:655-662.
7. Lautenbach E, Fishman NO, Bilker WS, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469-2477.
8. Heffelfinger JD, Dowell SB Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
9. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
10. Fishman N. Antimicrobial stewardship. Am J Infect Control. 2006;34 (5 suppl 1):S55-S63.
11. Metlay JB Camargo CA Jr, Bos K, Gonzales R. Assessing the suitability of intervention sites for quality improvement studies in emergency departments. Acad Emerg Med. 2005;12:667-670.
12. Gonzales R, Camargo CA Jr, MacKenzie T, et al. Antibiotic treatment of acute respiratory infections in acute care settings. Acad Emerg Med. 2006;13:288-294.
13. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons, Inc; 2000.
14. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice. Ann Intern Med. 2003;138:525-533.
15. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719-725.
16. Lautenbach E, Larosa LA, Kasbekar M, et el. Fluoroquinolone utilization in the emergency departments of academic medical centers. Arch Intern Med. 2003;163:601-605.
17. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347-382.
18. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-1433.
19. Grossman BF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med. 2005;118(suppl 7A):29S-38S.
20. Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med. 2005:118 (suppl 7A):39S-44S.
21. Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;346:988-994.
22. Lautenbach E, Fishman N, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469-2477.
23. Zervos MJ, Hershberger E, Nicolau DP, et el. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003;37:1643-1648.
24. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
25. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
26. Schumock GT, Walton SM, Park HY, et al. Factors that influence prescribing decisions. Ann Pharmacother. 2004;38:557-562.
27. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care. 2002;8:1041-1054.
28. . Houck PM, MacLehose RF, Niederanan SWS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119:1420-1426.
29. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med. 2006;119:859-864.
30. Raisch DW. A model of methods for influencing prescribing, part I: a review of prescribing models, persuasion theories, and administrative and educational methods. DICP. 1990;24:417-421.
31. Raisch DW. A model of methods for influencing prescribing, part II: a review of educational methods, theories of human inference, and delineation of the model. DICP. 1990;24:537-542.
32. Roumie CL, Halasa NB, Edwards KM, et al. Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med. 2005;118:641-648.
33. Thorpe JM, Smith SR, Trygetad TK. Trends in emergency department antibiotic prescribing for acute respiratory tract infections. Ann Pharmacother. 2004;38:928-935.
34. Ladd E. The use of antibiotics for viral upper respiratory tract infections: an analysis of nurse practitioner and physician prescribing practices in ambulatory care, 1997-2001. J Am Acad Nurse Pract. 2005;17:416-424.